Strs Ohio Prothena Corp Public LTD CO Transaction History

Strs Ohio

$25.5 Billion
Q3 2024

A detailed history of Strs Ohio transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Strs Ohio holds 11,200 shares of PRTA stock, worth $159,376. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,200

Previous 11,200 -0.0%

Holding current value

$159,376

Previous $231,000 19.05%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	BUY	$19.54 - $26.15 $21,494 - $28,765	1,100 Added 10.89%	11,200 $231,000
Q1 2024 May 13, 2024	SELL	$24.75 - $40.66 $14,850 - $24,395	-600 Reduced 5.61%	10,100 $250,000
Q4 2023 Jan 30, 2024	BUY	$32.31 - $52.32 $122,778 - $198,816	3,800 Added 55.07%	10,700 $388,000
Q3 2023 Oct 26, 2023	SELL	$47.3 - $70.6 $288,530 - $430,659	-6,100 Reduced 46.92%	6,900 $332,000
Q2 2023 Jul 31, 2023	BUY	$48.26 - $78.59 $24,130 - $39,295	500 Added 4.0%	13,000 $887,000
Q1 2023 Aug 02, 2023	SELL	$46.97 - $58.27 $23,485 - $29,135	-500 Reduced 3.85%	12,500 $605,000
Q4 2022 Jan 26, 2023	SELL	$52.05 - $65.0 $369,555 - $461,500	-7,100 Reduced 36.22%	12,500 $753,000
Q2 2022 Jul 25, 2022	BUY	$22.73 - $39.98 $72,736 - $127,935	3,200 Added 19.51%	19,600 $532,000
Q4 2021 Jan 24, 2022	BUY	$42.11 - $73.26 $113,697 - $197,802	2,700 Added 19.71%	16,400 $810,000
Q3 2021 Oct 22, 2021	BUY	$48.2 - $78.89 $607,320 - $994,014	12,600 Added 1145.45%	13,700 $975,000
Q2 2021 Jul 26, 2021	BUY	$21.63 - $57.65 $23,793 - $63,415	1,100 New	1,100 $56,000
Q4 2017 Jan 23, 2018	SELL	$35.44 - $63.76 $77,968 - $140,272	-2,200 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$53.83 - $67.75 $118,426 - $149,050	2,200	2,200 $142,000

Others Institutions Holding PRTA

# of Institutions

185

Shares Held

42.8M

Call Options Held

162K

Put Options Held

102K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $668M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account